NATION IN BRIEF : WASHINGTON, D.C. : Generic Drug Firm’s Lawyers Cite Deceit
From Times Staff and Wire Reports
Attorneys for Bolar Pharmaceutical Co., a New York firm seeking to keep its generic blood-pressure medication on the market, said in letters released by a House subcommittee that the company gave them phony test reports to show federal regulators. Bolar was already under federal scrutiny because of allegations that it used false documents to demonstrate to the Food and Drug Administration that its product is equivalent to Dyazide, made by Smithkline Beecham.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
